LUCID CAPITAL MARKETS Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Neutral 50.0%

Neg 0% Neu 50% Pos 0%

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces Price Target of $50.